MacroGenics Inc
$ 4.04
0.75%
07 Aug - close price
- Market Cap 256,795,000 USD
- Current Price $ 4.04
- High / Low $ 4.05 / 3.89
- Stock P/E N/A
- Book Value 0.33
- EPS -1.12
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -1.40 %
- 52 Week High 5.08
- 52 Week Low 1.29
About
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$6.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-09 | 2025-11-12 | 2025-08-14 | 2025-05-13 | 2025-03-20 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-07 | 2023-11-06 | 2023-08-09 |
| Reported EPS | -0.58 | -0.22 | 0.27 | -0.57 | -0.65 | -0.818 | 0.9 | -0.89 | -0.84 | -0.75 | -0.52 | -0.7 |
| Estimated EPS | -0.55 | -0.2696 | -0.44 | 0.38 | -0.69 | -0.59 | 0.6 | -0.59 | -0.64 | -0.15 | -0.35 | -0.5 |
| Surprise | -0.03 | 0.0496 | 0.71 | -0.95 | 0.04 | -0.228 | 0.3 | -0.3 | -0.2 | -0.6 | -0.17 | -0.2 |
| Surprise Percentage | -5.4545% | 18.3976% | 161.3636% | -250% | 5.7971% | -38.6441% | 50% | -50.8475% | -31.25% | -400% | -48.5714% | -40% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGNX
2026-08-03 20:42:44
A holder of MacroGenics Inc. (NASDAQ: MGNX) has filed a notice under Rule 144 to sell up to 20,166 shares of common stock through Merrill Lynch. The proposed sale date is August 3, 2026, on NASDAQ. These shares were acquired through stock plan activity on various dates, including May 20, 2024, May 20, 2025, and May 18, 2026.
2026-08-03 20:42:44
Bank of America Corporation has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock, which constitutes 4.0% of the class. This stake is held through various wholly-owned subsidiaries and Bank of America reports shared voting and dispositive power over these shares, confirming ownership of 5 percent or less of the class. The filing uses 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics' May 13, 2026 Form 10-Q for its calculations.
2026-08-01 02:42:44
TradingKey reports that MacroGenics Inc (MGNX) has a current financial score of 7.98, placing it 66th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 57.48% year-over-year increase, while net profit rose by 10.39% year-over-year. However, several key financial metrics such as cash and cash equivalents, total assets, total liabilities, free cash flow, operating profit, SG&A, cash flow from operating activities, and income after tax have not yet been disclosed by the company.
2026-07-29 19:15:35
BlackRock, Inc. has disclosed a 7.1% beneficial ownership stake in MacroGenics Inc. (MGNX), holding 4,503,913 shares of common stock as of June 30, 2026. This information was reported in a Schedule 13G filing, indicating that BlackRock has sole voting power over 4,447,312 shares and sole dispositive power over 4,503,913 shares. The filing states that no individual BlackRock client holds more than five percent of MacroGenics' outstanding common shares.
2026-07-29 14:10:13
This article provides a comprehensive stock analysis of MacroGenics Inc (MGNX) from TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status. Despite recent market weakness, the company's revenue and net income have seen significant growth, and analysts have issued "Buy" ratings with an average target price suggesting substantial upside. The analysis also details MacroGenics' product pipeline, including several monoclonal antibody-based therapeutics for cancer treatment.
2026-07-28 14:42:21
This article analyzes market sentiment for MacroGenics (MGNX) through analyst consensus, short interest, options flow, and recent insider activity. It highlights a "Buy" consensus from 14 analysts with an average price target of $8, significant short interest of 9.3%, and bullish options flow. The report also details recent analyst rating changes and mentions several insider buying activities involving MacroGenics.
